Rajiv Nayar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/914339/publications.pdf

Version: 2024-02-01

33 papers 1,171 citations

20 h-index 395702 33 g-index

34 all docs 34 docs citations

34 times ranked 1065 citing authors

#	Article	IF	CITATIONS
1	Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice. Pulmonary Pharmacology and Therapeutics, 2010, 23, 107-114.	2.6	22
2	Impact of bulking agents on the stability of a lyophilized monoclonal antibody. European Journal of Pharmaceutical Sciences, 2009, 38, 29-38.	4.0	53
3	Stability of a Trivalent Recombinant Protein Vaccine Formulation Against Botulinum Neurotoxin During Storage in Aqueous Solution. Journal of Pharmaceutical Sciences, 2009, 98, 2970-2993.	3.3	37
4	Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. Journal of Pharmaceutical Sciences, 2009, 98, 2994-3012.	3.3	23
5	Effect of pH on Stability of Recombinant Botulinum Serotype A Vaccine in Aqueous Solution and During Storage of Freezeâ€Dried Formulations. Journal of Pharmaceutical Sciences, 2008, 97, 5132-5146.	3.3	18
6	ACCELERATED DOSING FREQUENCY OF A PULMONARY FORMULATION OF TISSUE PLASMINOGEN ACTIVATOR IS WELLâ€₹OLERATED IN MICE. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 1454-1460.	1.9	9
7	Effects of solution conditions and surface chemistry on the adsorption of three recombinant botulinum neurotoxin antigens to aluminum salt adjuvants. Journal of Pharmaceutical Sciences, 2007, 96, 2375-2389.	3.3	15
8	Second virial coefficient determination of a therapeutic peptide by self-interaction chromatography. Biopolymers, 2006, 84, 527-533.	2.4	26
9	Effect of buffer species on the thermally induced aggregation of interferon-tau. Journal of Pharmaceutical Sciences, 2006, 95, 1212-1226.	3.3	48
10	Noninvasive Determination of Protein Conformation in the Solid State Using Near Infrared (NIR) Spectroscopy. Journal of Pharmaceutical Sciences, 2005, 94, 2030-2038.	3.3	46
11	Solution behavior of a novel type 1 interferon, interferon-Ï". Journal of Pharmaceutical Sciences, 2005, 94, 2703-2715.	3.3	27
12	Feasibility of Tissue Plasminogen Activator Formulated for Pulmonary Delivery. Pharmaceutical Research, 2005, 22, 1700-1707.	3.5	19
13	Infrared spectroscopic studies of protein formulations containing glycine. Journal of Pharmaceutical Sciences, 2004, 93, 1359-1366.	3.3	13
14	Quantification of glycine crystallinity by near-infrared (NIR) spectroscopy. Journal of Pharmaceutical Sciences, 2004, 93, 2439-2447.	3.3	38
15	A Novel Method for Removing Residual Acetone from Gelatin Microspheres. Pharmaceutical Development and Technology, 2002, 7, 169-180.	2.4	2
16	High Throughput Formulation: Strategies for Rapid Development of Stable Protein Products. Pharmaceutical Biotechnology, 2002, 13, 177-198.	0.3	12
17	Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. British Journal of Cancer, 1995, 71, 482-488.	6.4	53
18	Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemotherapy and Pharmacology, 1994, 34, 137-146.	2.3	53

#	Article	IF	CITATIONS
19	Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemotherapy and Pharmacology, 1993, 33, 17-24.	2.3	77
20	Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemotherapy and Pharmacology, 1990, 27, 13-19.	2.3	65
21	Retention of vital dyes correlates inversely with the multidrug-resistant phenotype of adriamycin-selected murine fibrosarcoma variants. Experimental Cell Research, 1990, 190, 69-75.	2.6	36
22	Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochimica Et Biophysica Acta - Biomembranes, 1990, 1023, 133-139.	2.6	95
23	Arrest and Retention of Multilamellar Liposomes in the Brain of Normal Mice or Mice Bearing Experimental Brain Metastases. Selective Cancer Therapeutics, 1989, 5, 73-79.	0.5	29
24	Binding of Liposomes to Human Bladder Tumor Epithelial Cell Lines: Implications for an Intravesical Drug Delivery System for the Treatment of Bladder Cancer. Selective Cancer Therapeutics, 1989, 5, 147-155.	0.5	20
25	Generation of large unilamellar vesicles from long-chain saturated phosphatidylcholines by extrusion technique. Biochimica Et Biophysica Acta - Biomembranes, 1989, 986, 200-206.	2.6	172
26	In vitro activation of tumoricidal properties in mouse macrophages using the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) incorporated in liposomes. Cancer Immunology, Immunotherapy, 1988, 27, 1-6.	4.2	6
27	N-Succinyldioleoylphosphatidylethanolamine: structural preferences in pure and mixed model membranes. Biochimica Et Biophysica Acta - Biomembranes, 1988, 937, 31-41.	2.6	8
28	Characterization of Liposomes Containing the Chemotactic Peptide N-formyl-methionylleucyl-phenylalanine (FMLP) and Their Interaction with Mouse Macrophages. Cancer Drug Delivery, 1987, 4, 233-244.	0.7	7
29	[42] Liposome encapsulation of muramyl peptides for activation of macrophage cytotoxic properties. Methods in Enzymology, 1986, 132, 594-603.	1.0	4
30	A microassay for the rapid and selective binding of cells from solid tumors to mouse macrophages. Cancer Immunology, Immunotherapy, 1986, 22, 125-31.	4.2	7
31	The systemic activation of macrophages by liposomes containing immunomodulators. Seminars in Immunopathology, 1985, 8, 413-428.	4.0	14
32	Generation of pH-sensitive liposomes: use of large unilamellar vesicles containing N-succinyldioleoylphosphatidylethanolamine. Biochemistry, 1985, 24, 5967-5971.	2.5	85
33	Phosphatidic acid as a calcium ionophore in large unilamellar vesicle systems. Biochimica Et Biophysica Acta - Biomembranes, 1984, 777, 343-346.	2.6	32